Drugs / NTS-104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05547438 | May → Dec 2023 | ischemic stroke | NeuroTrauma Sciences, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-07 | NeuroTrauma Sciences, LLC | Results NeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference neurotraumasciences.com ↗
Administration of NTS-104 following TBI or stroke in rats improves functional outcomes and lesion volume |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-01 | NeuroTrauma Sciences, LLC | NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104 neurotraumasciences.com ↗ |
| 2022-06-07 | NeuroTrauma Sciences, LLC | NeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference neurotraumasciences.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTS-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05547438 ↗ |
| Route | Intravenous | “single IV administration of NTS-104” NCT05547438 ↗ |